CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eutropics, Inc , (Cambridge, MA) and Tolero Pharmaceuticals, Inc, (Lehi, UT) announced today a strategic alliance to utilize Eutropics’ companion diagnostic approach to assist in the development of Tolero’s experimental therapeutics for hematological malignancies. Under the terms of the agreement, Eutropics’ proprietary biomarker platform, Praedicare-Dx , will be used to support the development of Tolero’s therapeutic portfolio, particularly Tolero’s Phase III ready asset, alvocidib. Alvocidib is an experimental therapeutic that has demonstrated clinical activity in patients with acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL). Patient stratification using Eutropics’ companion diagnostics approach will be explored as a way to improve patient care by matching specific therapies to the specific individuals most likely to benefit.
Help employers find you! Check out all the jobs and post your resume.
